优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%

智通财经
Jan 08

智通财经APP获悉,生物技术公司Immuneering Corp.(IMRX.US)在周三盘后交易中暴跌约21%,此前其公布了atebimetinib作为胰腺癌一线疗法的2a期临床试验结果。

该公司报告称,接受atebimetinib联合改良版吉西他滨/白蛋白结合型紫杉醇治疗的患者,12个月总生存率为64%。公司指出,目前标准疗法在12个月的总生存率基准为35%。

此外,该联合疗法的12个月总缓解率为39%,而标准疗法为23%。其中位无进展生存期为8.5个月,优于标准疗法的5.5个月。Immuneering特别指出,在超过10%的患者中仅观察到两种3级不良事件,即中性粒细胞减少症和贫血。

尽管atebimetinib的数据表现良好,但投资者可能将其与处于开发阶段的其他胰腺癌一线疗法进行对比,例如Verastem的avutometinib联合defactinib方案以及Revolution Medicines的daraxonarasib。其中,avutometinib联合疗法此前报告的总缓解率达83%,daraxonarasib则为55%。不过,Verastem和Revolution Medicines所公布结果的中位随访时间相对较短。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10